Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer

Autor: Rachel Yoder, Bruce F. Kimler, Joshua M. Staley, Kelsey Schwensen, Yen Y. Wang, Karissa Finke, Anne O’Dea, Lauren Nye, Manana Elia, Gregory Crane, Richard McKittrick, Robert Pluenneke, Sheshadri Madhusudhana, Larry Beck, Anuj Shrestha, Larry Corum, Mark Marsico, Shane R. Stecklein, Andrew K. Godwin, Qamar J. Khan, Priyanka Sharma

Publikováno v: npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)

Abstract Triple-negative breast cancer (TNBC) is classically defined by estrogen receptor (ER) and progesterone receptor (PR) immunohistochemistry expression

Externí odkaz: https://doaj.org/article/cff802109f0d4e06a3ba6f327f1d9180

Data from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

Autor: Andrew K. Godwin, Qamar J. Khan, Bruce F. Kimler, Gregory A. Reed, Milind A. Phadnis, Stephen K. Williamson, Stephanie LaFaver, Jaimie Heldstab, Karissa Finke, Kelsey Schwensen, Rachel Yoder, Yen Y. Wang, Jilliann A. De Jong, Jecinta Scott, Sharon Lewis, Manana Elia, Shane R. Stecklein, Marc Hoffmann, Harsh B. Pathak, Ingrid Mayer, Lauren Nye, Anne O'Dea, Vandana G. Abramson, Priyanka Sharma

Purpose:PIK3CA mutations are common in breast cancer and promote tumor progression and treatment resistance. We conducted a phase I/II trial of alpelisib (α-specific PI3K inhibitor) plus nab-paclitaxel in patients with HER2-negative metastatic breas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5663202857f8528f331d69cee18ca0d
https://doi.org/10.1158/1078-0432.c.6530748

Supplementary Figure 3 from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

Autor: Andrew K. Godwin, Qamar J. Khan, Bruce F. Kimler, Gregory A. Reed, Milind A. Phadnis, Stephen K. Williamson, Stephanie LaFaver, Jaimie Heldstab, Karissa Finke, Kelsey Schwensen, Rachel Yoder, Yen Y. Wang, Jilliann A. De Jong, Jecinta Scott, Sharon Lewis, Manana Elia, Shane R. Stecklein, Marc Hoffmann, Harsh B. Pathak, Ingrid Mayer, Lauren Nye, Anne O'Dea, Vandana G. Abramson, Priyanka Sharma

Gene expression signatures by PIK3CA mutation status

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2222390849891e00adf02280b04f90c4
https://doi.org/10.1158/1078-0432.22481643

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer:a multicentre pooled analysis of 5161 patients

Autor: Christina Yau, Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze, Anne-Sophie Hamy, Marick Laé, Fabien Reyal, Gabe S Sonke, Tessa G Steenbruggen, Maartje van Seijen, Jelle Wesseling, Miguel Martín, Maria del Monte-Millán, Sara López-Tarruella, Judy C Boughey, Matthew P Goetz, Tanya Hoskin, Rebekah Gould, Vicente Valero, Stephen B Edge, Jean E Abraham, John M S Bartlett, Carlos Caldas, Janet Dunn, Helena Earl, Larry Hayward, Louise Hiller, Elena Provenzano, Stephen-John Sammut, Jeremy S Thomas, David Cameron, Ashley Graham, Peter Hall, Lorna Mackintosh, Fang Fan, Andrew K Godwin, Kelsey Schwensen, Priyanka Sharma, Angela M DeMichele, Kimberly Cole, Lajos Pusztai, Mi-Ok Kim, Laura J van 't Veer, Laura J Esserman, W Fraser Symmans, Kathi Adamson, Kathy S. Albain, Adam L. Asare, Smita M. Asare, Ron Balassanian, Heather Beckwith, Scott M. Berry, Donald A. Berry, Judy C. Boughey, Meredith B. Buxton, Yunn-Yi Chen, Beiyun Chen, A. Jo Chien, Stephen Y. Chui, Amy S. Clark, Julia L. Clennell, Brian Datnow, Angela M. DeMichele, Xiuzhen Duan, Kirsten K. Edmiston, Anthony D. Elias, Erin D. Ellis, Laura L. Esserman, David M. Euhus, Oluwole Fadare, Michael D Feldman, Andres Forero-Torres, Barbara B. Haley, Hyo S. Han, Shuko Harada, Patricia Haugen, Teresa Helsten, Gillian L. Hirst, Nola M. Hylton, Claudine Isaacs, Kathleen Kemmer, Qamar J. Khan, Laila Khazai, Molly E. Klein, Gregor Krings, Julie E. Lang, Lauren G. LeBeau, Brian Leyland-Jones, Minetta C. Liu, Shelly Lo, Janice Lu, Anthony Magliocco, Jeffrey B. Matthews, Michelle E. Melisko, Paulette Mhawech-Fauceglia, Stacy L. Moulder, Rashmi K. Murthy, Rita Nanda, Donald W. Northfelt, Idris T. Ocal, Olufunmilayo Olopade, Stefan Pambuccian, Melissa Paoloni, John W. Park, Barbara A. Parker, Jane Perlmutter, Garry Peterson, Mara Rendi, Hope S. Rugo, Sunati Sahoo, Sharon Sams, Ashish Sanil, Husain Sattar, Richard B. Schwab, Ruby Singhrao, Katherine Steeg, Erica Stringer-Reasor, W. Fraser Symmans, Ossama Tawfik, Debasish Tripathy, Megan L. Troxell, Laura J. van't Veer, Sara J. Venters, Tuyethoa Vinh, Rebecca K. Viscusi, Anne M. Wallace, Shi Wei, Amy Wilson, Douglas Yee, Jay C. Zeck

Publikováno v: I-SPY 2 Trial Consortium 2022, ' Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer : a multicentre pooled analysis of 5161 patients ', The Lancet Oncology, vol. 23, no. 1, pp. 149-160 . https://doi.org/10.1016/S1470-2045(21)00589-1
The Lancet. Oncology, vol 23, iss 1
The Lancet Oncology, 23(1), 149-160. Lancet Publishing Group

Background: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the rel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9b5a03d8d05046179f5dcc364471bd0
https://research.vumc.nl/en/publications/4b35d135-33e6-4bf5-982e-dab0f5ddbfd8

Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

Autor: Yen Y. Wang, Stephen K. Williamson, Karissa Finke, Jecinta Scott, Bruce F. Kimler, Priyanka Sharma, Andrew K. Godwin, Gregory A. Reed, Marc Hoffmann, Shane R. Stecklein, Rachel Yoder, Lauren Nye, Anne O'Dea, Qamar J. Khan, Sharon Lewis, Milind A. Phadnis, Stephanie LaFaver, Jaimie Heldstab, Jilliann A De Jong, Ingrid A. Mayer, Manana Elia, Vandana G Abramson, Harsh B. Pathak, Kelsey Schwensen

Publikováno v: Clin Cancer Res

Purpose:PIK3CA mutations are common in breast cancer and promote tumor progression and treatment resistance. We conducted a phase I/II trial of alpelisib (α-specific PI3K inhibitor) plus nab-paclitaxel in patients with HER2-negative metastatic breas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c92ce83021f467a43a026db8bba23a56
https://pubmed.ncbi.nlm.nih.gov/33602685